Brain derived neurotrophic factor (BDNF) levels in depressed women treated with open-label escitalopram

Recent studies suggest the important role of brain derived neurotrophic factor (BDNF) in the etiopathogenesis of major depressive disorder (MDD) and the mechanism of action of antidepressants. This study aimed to correlate serum levels of BDNF and clinical symptoms in patients with MDD before and after 6 months treatment with escitalopram.

Twenty women diagnosed with MDD and 20 aged-matched healthy female controls were recruited. The patients received escitalopram 10-20 mg/day. BDNF serum levels were measured at inclusion, week 4, week 12 and week 24. The Montgomery-Åsberg Depression Rating Scale (MADRS) was used to assess the severity of depressive symptoms and the clinical evolution of patients. Statistical analysis was performed using both observed cases and last observation carried forward.

At baseline, low serum levels of BDNF were associated with MDD. In women with MDD, escitalopram seems to have a positive effect on BDNF serum levels in parallel with the clinical response.

This study suggests that a good clinical evolution under treatment with escitalopram might be associated with increases of BDNF levels in female patients.